NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common... [read full story]
|
RELATED
|
|
Seaside Therapeutics LLC announced that the Company has initiated a Phase 1 clinical trial of STX107, a highly potent, selective mGluR5 antagonist, in development for the treatment of Fragile X Syndrome. The single ascending...
NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common...
NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common...
In his own words, MIT neuroscientist Mark Bear admits he did not "wake up one day and say 'Hey, I'm going to cure autism.'" But, after decades of painstaking basic research on how the brain rewires itself in response to...
NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common...
NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common...
Seaside Therapeutics LLC today announced that the Company has initiated a Phase 1 clinical trial of STX107, a highly potent, selective mGluR5 antagonist, in development for the treatment of Fragile X Syndrome. The single...
NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common...
Scientists are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date...
In his own words, MIT neuroscientist Mark Bear admits he did not “wake up one day and say ‘Hey, I’m going to cure autism.’” But, after decades of painstaking basic research on how the brain rewires itself in response to...
Ambulatory Health Care, Scientific Discoveries, Health Care, Learning Disorders, Childhood Diseases & Disorders, Humanitarian & Development Assistance, Genetics and Birth Defects, Mental Health & Behavior, Pharmaceuticals, Scientists, Child Health, Medical Research, Massachusetts, United States of America, North America, Cambridge (Massachusetts)
